Alan I see the point you are trying to make. But let me point out compete response rate in stage IV melanoma PV-10/ Keytruda combo P1. Not all tumors had a location where they could be injected by PV-10. Those tumors that were not injected by PV-10 but had Keytruda in the blood stream had a paltry 8% complete response rate....which is about right for Keytruda. Now for the PV-10 injected lesions and having Keytruda in the blood stream....this resulted in 75% complete response rate....and a 81% DCR.
In the mum trial....in monotherapy...those patients had a 50% DCR.
In HCC we have complete responses going on over 8 years.
But you are right.....not enough N for a big buyout likely....but perhaps enough at the end of all the P1ís to get a big pharma to a deal to fund the P2ís quickly to a point where the bigger money lies.